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Abstract
Background: Ginsenoside Rb1, a principle active ingredients of Panax ginseng, has been shown to lower blood
glucose in animals and increase insulin secretion in cultured insulinoma cells. The aim of this study was to
determine the effects of daily ginsenoside Rb1 supplementation on circulating glucose and insulin levels in men
during a 5-day recovery period after an acute bout of resistance exercise.
Methods: Twelve gymnasts (20.5 ± 0.3 years of age) participated in this double blind placebo-controlled crossover
trial. They were challenged by a lower-limb resistance exercise at a weight load of 85 % one-repetition maximal
(1-RM) for 10 repetitions, six sets of the movement. Rb1 (1 ng/kg) or Placebo was orally delivered to participants
daily during a 5-day recovery period after challenge. Circulating insulin, glucose and heart rate variability (HRV)
were measured under fasted condition in the morning at Days 1, Day 3, and Day 5 during recovery.
Results: No significant effect of Rb1 on circulating glucose and insulin levels were found among participants
during the 5-day recovery period. A persistent elevation in sympathetic nervous activity, indicated by increased
HRV-low frequency/high frequency (HRV-LF/HF) power, during the Rb1 trial was observed.
Conclusions: The result of the study suggests that the null effect of Rb1 supplementation on lowering glucose
and insulin levels of participants may be associated with chronic sympathetic activation.
Background
Existing scientific literatures regarding glucose-lowering
effect of ginseng in humans present conflicting results
[1, 2]. Variation in ginsenoside profile associated with
different species and cultivating season may account for
the discrepancy among previous studies [1, 3]. Ginsenoside
Rb1 is one of the most abundant ginsenosides in ginseng
[4], which has been reported to stimulate insulin secretion
in cultured Min6 cells [5] and decrease fasting glucose
in rats [6]. To the best of our knowledge, no published
data is currently available regarding whether oral Rb1
supplementation can affect circulating glucose and insulin
levels in humans. Pancreatic insulin secretion and insulin
sensitivity are, to some extent, modulated by autonomic
nervous activity [7–10]. Despite effect of Rb1 on auto-
nomic nervous activity is currently unknown, ginseng
extract has been shown to influence the human auto-
nomic nervous system reflected by heart rate variability
analysis [11]. It has been reported that exercise contain-
ing eccentric contraction elicited a decreased insulin
sensitivity in the whole-body glucose disposal [12]. The
present work was undertaken to determine the effect of
oral Rb1 supplementation on the glucose and insulin
levels in athletes during a 5-day recovery period after a
resistance exercise bout containing dynamic (concentric
and eccentric) contraction of the lower extremities.
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Twelve male college gymnasts (aged 20.5 ± 0.3 y; height
169.4 ± 1.6 cm; weight 63.4 ± 1.8 kg) volunteered to
participate in this study. Prior to the recruitment of
volunteers, the study protocol was approved by Institu-
tional Review Board of University of Taipei, Taipei,
Taiwan. A detailed explanation of the study procedures,
including the supplements to be received and potential
risks might be involved, was informed to all participants
prior to study. All subjects completed a written informed
screening questionnaire after explanation. Participants
had any form of health problem were precluded. All
participants were asked not to change their dietary habit
and not to participate in any form of training activity
since a week before trial until the end of blood sample
collection.
Experimental design
This study used a placebo-controlled, double-blind,
crossover design with a two-week washout period. Partici-
pants were randomly assigned to one of two parallel
groups, initially in 1:1 ratio, to receive either Rb1 or
Placebo under supervision of a lab staff to ensure subject
compliance. The Rb1 and Placebo were made by the lab
manager in liquid form and were identical in appearance.
They were placed in a container and consecutively num-
bered for each participant according to the randomization
schedule. Each participant was assigned an order number
and received the drink in the corresponding container.
A computer-generated list of random numbers was used
for allocation of the participants. A research staff assigned
participants to interventions. Except for the interventions,
staff was kept blind to supplement assignment of the
participants. Staff that takes outcome measurements and
staff that delivers the intervention was different. Staffs
and participants were maintained masked to outcome
measurements and trial results. Before the experiment
began, all participants engaged in parallel squatting and
their 85 % maximum lower-limb muscle strength (85 % of
1-RM) was assessed. Baseline assessments was conducted
under overnight fasted condition. Following a 30-min
warm up period consisting of a 5-min warm up, a 10-min
full-body stretching, a 5-min lower body stretching, a
5-min low intensity squat practice and a 5-min rest,
all participants were challenged with a single bout of
high-intensity lower-limb resistance exercise. In brief,
this resistance exercise consisted of 6 sets of parallel
squats with a resting interval of 60 s between sets [13].
Each exercise set comprised of a 10-parallel squat
repetitions at 85 % one-repetition maximal (1-RM). All
participants were instructed to complete each set of squat
repetitions within 60 s.
Rb1 supplementation
Following exercise challenge, each participant was
instructed to consume a solution containing ginsenoside
Rb1 (or a placebo solution) for 5 consecutive days. Rb1
and Placebo drinks were made available by 0900 am in
the morning. Participants orally received the drink once
daily in the lab, under supervision of a staff at 0900 am
during the 5-day recovery period. The Rb1, provided by
NuLiv Science (Walnut, CA, USA), was extracted from
Asian ginseng. Rb1 content is confirmed by Prof Tsu-
Chung Chang in Department of Biochemistry, National
Defense Medical College, Taiwan [14]. Rb1 crystal was
solubilized by a 58 % alcohol solution into a concentrate.
They were then withdrawn by pipetting into 50 ml of
drinking water to achieve a final dose of 1 ng/kg body
weight for each participants. The placebo group con-
sumed same volume of drinking water, which contained
an identical amount of alcohol solution. Participants
were unable to tell the difference between Rb1 and
Placebo drinks by appearance and taste. The experimen-
tal procedure is shown in Fig. 1. The dosage used in this
study is equivalent to approximately 0.1 g of ginseng
(wet weight), which is considered low dose.
Samples collection
Blood samples were collected from fingertip and mea-
sured immediately for glucose concentration. Serum
sample was used for insulin and cortisol measurements.
A total of 200 μl of blood was collected from the fingertip
for serum preparation, before and 10-min, 1 day, 3 day,
and 5 days after resistance exercise challenge [13]. Each
blood sample was centrifuged at 4000 rpm for 5 min.
Supernatants were used as serum samples for insulin and
cortisol measurements. They were frozen at −80 °C and
analyzed within a week.
Biochemical analysis
Fasting blood glucose was analyzed using a glucose-
oxidase method with the One-Touch glucometer (Life-
Scan, Milpitas, CA, USA). All hormones were measured
using commercially available enzyme-linked immuno-
sorbent assay (ELISA) kits (Diagnostics Systems Labora-
tories, Inc., Webster, TX, USA) according to the standard
procedures provided by the manufacturer. In brief, serum
samples (depending on the requirements for specific kits)
were loaded into 96-well plates coated with specific
antibodies. Once antigens were bound with the specific
primary antibody, the secondary antibody was added to
form the antibody-antigen-antibody complex. The en-
zyme was then added and conjugated to the secondary
antibody, and the plates were finally developed by adding
enzyme substrate to generate visual light signals. The vis-
ual light signals were detected by ELISA analyzer (Tecan
Genios, Salzburg, Austria). The intra-assay coefficient of
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variances (CV) for insulin and cortisol were 2.03 and
5.90 %, respectively.
Heart rate variability (HRV)
HRV of all participants was assessed before (09:00), after
exercise (11:50) and on the Day 1, Day 3 and Day 5 dur-
ing recovery period (09:00). HRV was assessed in a quiet,
dim environment at room temperature. Prior to assess-
ment, participants were seated and instructed to relax for
5 min. An autonomic nervous system analyzer (Telemedi-
cine Equipment Co., Ltd., Taiwan) was used to acquire a
5-min R-R interval data. HRV-HF was considered to
be a measure of parasympathetic nervous system activity,
whereas HRV-LF/HF was considered to be a measure of
sympathetic nervous system activity [15].
Statistical analyses
Two-way ANOVA with repeated measure (Rb1 supple-
mentation and time) was performed to assess mean
differences in all variables. Fisher’s least significant dif-
ference test was performed for post hoc comparison.
Paired t-test was used to compare difference in area
under the curve (AUC) of HRV-LF/HF. All values were
expressed as mean ± standard error (SE). The statistical
significance was set at 5 % of type I error.
Results and discussion
Timeline of experimental procedure and blood sampling
is illustrated in Fig. 1. Time course data on circulating
glucose and insulin are illustrated in Figs. 2 and 3, respect-
ively. Both glucose and insulin concentrations between
Rb1 and Placebo trials were not different throughout the
5-day recovery period. Cortisol data are illustrated in
Fig. 4. No significant difference between trials was found
during the 5-day recovery period. Effect of Rb1 on
autonomic modulation is based on time course data from
HRV analysis. Rb1 had no significant effect on vagal power
(HRV-HF) during the recovery period (Fig. 5). However,
sympathetic power (HRV-LF/HF) during Rb1 trial was
significantly increased above Placebo level (Fig. 6). A
significant trial effect was detected (P < 0.05).
We hypothesized that Rb1 would increase insulin and
decrease glucose in men after a resistance exercise, based
on the existing data showing lowered blood glucose in rats
[16] and increased insulin secretion in cultured insuli-
noma cells [5] after Rb1 treatment. However, we did not
detect significant change in circulating glucose and insulin
during the 5-day Rb1 human trial. Our result is similar to
two studies using crude material of ginseng, which shows
no improvement in glucose metabolism of cyclists for
a 7-day Rb1 trial [17, 18]. Given the fact that Rb1 is
a major component of ginseng, the result of the study
implicates that Rb1 from ginseng cannot influence
Fig. 1 Experimental procedure. Post-exercise blood sample collection conducted before Rb1 or Placebo supplementation. Pre: before exercise;
Post: after exercise; Day 1, Day 3, and Day 5: post-exercise recovery time with Rb1 or Placebo supplementation
Fig. 2 Blood glucose levels during a 5-day Rb1 supplementation
after an acute bout of resistance exercise. All values are presented as
mean ± SE. SI unit conversion factor from mg/dL to mmol/L: 0.0555
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glucose and insulin in humans during an exercise
recovery at this dose.
Sympathetic activation by Rb1 may be one reason to
explain such unanticipated outcome for the absence of
glucose-lowering effect. Increased sympathetic activity is
generally associated with reduced insulin sensitivity in
humans [8], which is also supported by a causal relation-
ship of an increased insulin sensitivity by sympathetic
inhibition in obese patients [19]. Ginseng is known as a
modulator for the autonomic nervous system [11]. Thus,
result of the present study on persistent sympathetic
activation suggests that Rb1 is an active component of
ginseng and mediated its action via autonomic modula-
tion, which masks our observation on glucose lowering
action of Rb1.
Despite ginseng action on glucose metabolism being
widely studied subject for human use, most available
data come from studies using raw material or extract.
One major barrier to establish the knowledge regarding
whether ginseng can be designed as a hypoglycemic agent
is the variation of ginseng source. In a double-blind,
randomized, multiple-crossover trial, healthy participants
received the same amount of American, American-
wild, Asian, Asian-red, Japanese-rhizome, Vietnamese-
wild, Sanchi, Siberian ginsengs and Placebo, and showed
mixed outcomes on glucose tolerance [1]. Ginseng from
the same cultivated land but different batch can also
generate inconsistent outcomes on glucose tolerance in
humans [3]. Such discrepancy is presumably associated
with the changing ginsenoside profile due to season,
suggested by the observation that ineffective ginseng batch
on improving glucose tolerance also contains decreased
ginsenoside content including Rb1 than those effective
ginseng batch.
Despite the result of our study does not favor Rb1 as a
hypoglycemic component of ginseng as suggested by afore-
mentioned animal studies, we do not preclude the possibil-
ity that this ginsenoside component of ginseng may have
its claimed action at different doses. The current dose of
the study for our human participants was 1 ng/kg. Most of
the effective doses tested in previous animal studies are in
the range between 5–60 mg/kg, which is substantially
greater than what we have been used in the present study
[6, 20, 21]. Due to this limitation, dose–response human
trial would be needed for further clarification.
Ginseng supplementation has been reported to decrease
cortisol levels in humans [22–24]. Since cortisol is a po-
tent stress hormone that stimulates hepatic glucose output
and causes peripheral insulin resistance, we were expect-
ing a decrease of cortisol by Rb1 treatment. However,
no significant change was detected during the 5-day
human trial.
Conclusions
The present study asks the question whether ginsenoside
Rb1 can influence systemic glucose or insulin levels in
Fig. 3 Serum insulin levels during a 5-day Rb1 supplementation after
an acute bout of resistance exercise. All values are presented as
mean ± SE. SI unit conversion factor from μIU/mL to pmol/L: 6.945
Fig. 4 Serum cortisol levels during a 5-day Rb1 supplementation
after an acute bout of resistance exercise. All values are presented
as mean ± SE. SI unit conversion factor from μg/dL to nmol/L: 27.59
Fig. 5 Vagal modulation (HRV-HF) during a 5-day Rb1 supplementation
after an acute bout of resistance exercise. All values are presented
as mean ± SE
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humans after an acute bout of resistance exercise, based
on the findings of increased insulin release in pancreatic
cells and decreased blood glucose level in rats. However,
our data did not find any changes in circulating glucose
and insulin levels with a low dose Rb1 supplementation.
This result may be explained by a persistent elevation in
sympathetic nervous activity by Rb1 supplementation.
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